曼恩凯德生物医疗 MNKD 深 沪
已收盘 08-01 16:00:00 美东时间
3.75
-0.030
-0.79%
华盛通- 最 高3.81
- 今 开3.77
- 成交量 254.65万股
- 最 低 3.70
- 昨 收 3.78
- 总市值 11.40亿
- 52周最高 7.63
- 市盈率 静 38.58
- 换手率 0.84%
- 52周最低 3.51
- 委 比 99.11%
- 总股本 3.04亿
- 历史最高 57.40
- 量 比 0.94
- 振 幅 2.91%
- 历史最低 0.666
- 每 手 1
- 风险率 1.04%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025
MannKind Corporation announced the release of its second-quarter 2025 financial results on August 6, 2025, before market open. A webcast discussion of the results and business update will be held at 9:00 a.m. ET, accessible via MannKind’s website. A replay will be available within 24 hours and archived for 90 days. MannKind focuses on developing innovative inhaled therapies for endocrine and orphan lung diseases, leveraging dry-powder formulation...
07-30 20:05
RBC Capital Maintains Outperform on MannKind, Lowers Price Target to $8
RBC Capital analyst Douglas Miehm maintains MannKind (NASDAQ:MNKD) with a Outperform and lowers the price target from $10 to $8.
07-23 21:05
HC Wainwright & Co. Assumes MannKind at Buy, Announces Price Target of $9
HC Wainwright & Co. analyst Brandon Folkes assumes MannKind (NASDAQ:MNKD) with a Buy rating and announces Price Target of $9.
07-16 19:24
CEL-SCI announces pricing of $5.7 million offering
CEL-SCI (NYSE:CVM) announced on Friday the pricing of a best-efforts offering of 1,500,000 shares of its common stock. Each share of common stock is being sold at an offering price of $3.82 per share,...
07-12 03:04
Nektar Therapeutics surge continues as stock up another 25%
Nektar Therapeutics (NASDAQ:NKTR), which closed Tuesday up ~156% after its lead asset, rezpegaldesleukin, met its main goal in a mid-stage trial for atopic dermatitis, also known as eczema, is up anot...
06-26 02:14
Gene editors steady despite latest leadership shake-up at FDA
Shares of gene editing companies were largely steady in the premarket on Friday after the FDA’s Center for Biologics Research and Evaluation (CBER) faced another abrupt leadership transition following...
06-20 20:39
Ocugen gets FDA clearance to begin mid-stage study of OCU410ST
Ocugen (NASDAQ:OCGN) said on Monday that the U.S. FDA has cleared the company to initiate a phase 2/3 confirmatory trial of its modifier gene therapy, OCU410ST, to treat Stargardt disease, an eye diso...
06-16 21:38
Top 3 Health Care Stocks That May Rocket Higher This Quarter
The most oversold stocks in the health care sector presents an opportunity to b...
06-11 19:01
MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association’s 85th Scientific Sessions in Chicago, June 20-23
MannKind Corporation will showcase inhaled insulin at the American Diabetes Association’s 85th Scientific Sessions in Chicago from June 20-23. Dr. Michael J. Haller will present results from the Phase 3 INHALE-1 study of Afrezza in children and adolescents. Additional presentations will cover patient-reported outcomes and the efficacy of Afrezza in adults with T2DM. MannKind will also host a booth for scientific discussions. The company expects t...
06-09 20:05
Ocugen signs license deal with Korean company for gene therapy
Ocugen (NASDAQ:OCGN) said on Thursday that it has signed a term sheet to negotiate a licensing deal with a pharmaceutical company in Korea. This agreement will grant exclusive Korean rights to OCU400...
06-05 21:32
